Celularity

Celularity Net Debt/Equity

The Net Debt to Equity Ratio of Celularity (CELU) as of Oct 16, 2026 is -0.91. In the previous year, Net Debt to Equity Ratio was 7.71 — a change of -111.84% (lower).

Net Debt/Equity

-0.91

YoY

-111.84%

Last updated:

Net Debt to Equity Ratio of Celularity is 2025 -0.91 . Net Debt to Equity Ratio of Celularity was 2024 7.71 . It decreases by -111.84% lower compared to the previous year.

The Celularity Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2018
-1.00 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-1.26 USD
Jan 1, 2021
-0.06 USD
Jan 1, 2022
0.26 USD
Jan 1, 2024
7.71 USD
Jan 1, 2025
-0.91 USD
The Celularity Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.91-111.84%
7.71+2,869.15%
0.26-522.72%
-0.06-95.15%
-1.26+264,102.63%
-0.00-99.95%
-1.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celularity Stock analysis

What does Celularity do? Celularity Inc, listed on the stock market with ticker CELU and ISIN US1511902041, is a biotechnology company headquartered in Florham Park, New Jersey, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Celularity has 225 employees and completed its initial public offering (IPO) on May 23, 2019. The company focuses on developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune disorders, and infectious diseases. Its research and development efforts include various therapy product candidates such as T cells engineered with a chimeric antigen receptor (CAR), natural killer cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target a range of conditions including cancer, infectious diseases, and degenerative diseases. Celularity's product pipeline features several programs, including CYCART-19, which is a placental-derived CAR-T cell therapy targeting B-cell malignancies, and pEXO-001, among others. The company's operations are structured around three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Celularity's website is https://celularity.com/. Celularity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celularity stock

Net Debt to Equity Ratio of Celularity is -0.91 in 2025.

Net Debt to Equity Ratio of Celularity changed from 7.71 to -0.91, representing a -111.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Celularity since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Celularity with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Celularity

All Key Metrics — Celularity